{"id":168454,"date":"2026-07-28T14:04:27","date_gmt":"2026-07-28T14:04:27","guid":{"rendered":"https:\/\/pabau.com\/?p=168454"},"modified":"2026-08-17T12:08:21","modified_gmt":"2026-08-17T12:08:21","slug":"hcpcs-code-j2354","status":"publish","type":"post","link":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/","title":{"rendered":"HCPCS Code J2354: Octreotide non-depot injection billing guide"},"content":{"rendered":"\n<script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"MedicalWebPage\",\"headline\":\"HCPCS Code J2354: Octreotide non-depot injection billing guide\",\"description\":\"HCPCS Code J2354 covers injection of octreotide acetate (non-depot form, 25 mcg per unit) administered subcutaneously or intravenously. Learn Medicare reimbursement, ICD-10 codes, and billing guidelines.\",\"url\":\"https:\/\/pabau.com\/procedure-codes\/hcpcs-code-j2354\/\",\"audience\":{\"@type\":\"MedicalAudience\",\"audienceType\":\"Clinician\"},\"reviewedBy\":{\"@type\":\"Person\",\"name\":\"Dr Vanja Kitanova\",\"jobTitle\":\"Medical Reviewer\",\"affiliation\":{\"@type\":\"Organization\",\"name\":\"Pabau\"},\"knowsAbout\":[\"Medical Coding\",\"Clinical Documentation\",\"Healthcare Billing\",\"Clinical Safety\"],\"sameAs\":\"https:\/\/pabau.com\/blog\/author\/vanja\/\"},\"datePublished\":\"2026-07-28\",\"dateModified\":\"2026-07-28\"}<\/script>\n\n\n        <div id=\"key_takeaways\">\n            <div class=\"header\">\n                                    <img decoding=\"async\" src=\"https:\/\/pabau.com\/wp-content\/uploads\/2025\/12\/Key-Takeaways-Icon.svg\" alt=\"Key takeaways\" height=\"42\" width=\"42\">\n                                <h3>Key takeaways<\/h3>\n            <\/div>\n            <div class=\"list\">\n                                                            <div class=\"item\">\n                            <div>\n                                <svg width=\"20\" height=\"27\" viewBox=\"0 0 20 27\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                                    <path\n                                        d=\"M18.6223 14.3857C19.1246 13.8975 19.1246 13.1045 18.6223 12.6162L12.1938 6.36621C11.6915 5.87793 10.8759 5.87793 10.3737 6.36621C9.87143 6.85449 9.87143 7.64746 10.3737 8.13574L14.6125 12.2529H2.28571C1.57455 12.2529 1 12.8115 1 13.5029C1 14.1943 1.57455 14.7529 2.28571 14.7529H14.6085L10.3777 18.8701C9.87545 19.3584 9.87545 20.1514 10.3777 20.6396C10.8799 21.1279 11.6955 21.1279 12.1978 20.6396L18.6263 14.3896L18.6223 14.3857Z\"\n                                        fill=\"#3D3D46\" \/>\n                                <\/svg>\n                            <\/div>\n                            <p>HCPCS Code J2354 describes injection of octreotide acetate in non-depot form, 25 mcg per unit, via subcutaneous or intravenous route.<\/p>\n                        <\/div>\n                                                                                <div class=\"item\">\n                            <div>\n                                <svg width=\"20\" height=\"27\" viewBox=\"0 0 20 27\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                                    <path\n                                        d=\"M18.6223 14.3857C19.1246 13.8975 19.1246 13.1045 18.6223 12.6162L12.1938 6.36621C11.6915 5.87793 10.8759 5.87793 10.3737 6.36621C9.87143 6.85449 9.87143 7.64746 10.3737 8.13574L14.6125 12.2529H2.28571C1.57455 12.2529 1 12.8115 1 13.5029C1 14.1943 1.57455 14.7529 2.28571 14.7529H14.6085L10.3777 18.8701C9.87545 19.3584 9.87545 20.1514 10.3777 20.6396C10.8799 21.1279 11.6955 21.1279 12.1978 20.6396L18.6263 14.3896L18.6223 14.3857Z\"\n                                        fill=\"#3D3D46\" \/>\n                                <\/svg>\n                            <\/div>\n                            <p>Each billing unit equals exactly 25 mcg. Divide the prescribed dose by 25 to calculate units, and verify the total against the prescribing order before submitting.<\/p>\n                        <\/div>\n                                                                                <div class=\"item\">\n                            <div>\n                                <svg width=\"20\" height=\"27\" viewBox=\"0 0 20 27\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                                    <path\n                                        d=\"M18.6223 14.3857C19.1246 13.8975 19.1246 13.1045 18.6223 12.6162L12.1938 6.36621C11.6915 5.87793 10.8759 5.87793 10.3737 6.36621C9.87143 6.85449 9.87143 7.64746 10.3737 8.13574L14.6125 12.2529H2.28571C1.57455 12.2529 1 12.8115 1 13.5029C1 14.1943 1.57455 14.7529 2.28571 14.7529H14.6085L10.3777 18.8701C9.87545 19.3584 9.87545 20.1514 10.3777 20.6396C10.8799 21.1279 11.6955 21.1279 12.1978 20.6396L18.6263 14.3896L18.6223 14.3857Z\"\n                                        fill=\"#3D3D46\" \/>\n                                <\/svg>\n                            <\/div>\n                            <p>Confusing J2354 (non-depot) with J2353 (depot\/LAR form) is the most common denial trigger, since the two formulations have different dosing intervals and reimbursement rates.<\/p>\n                        <\/div>\n                                                                                <div class=\"item\">\n                            <div>\n                                <svg width=\"20\" height=\"27\" viewBox=\"0 0 20 27\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                                    <path\n                                        d=\"M18.6223 14.3857C19.1246 13.8975 19.1246 13.1045 18.6223 12.6162L12.1938 6.36621C11.6915 5.87793 10.8759 5.87793 10.3737 6.36621C9.87143 6.85449 9.87143 7.64746 10.3737 8.13574L14.6125 12.2529H2.28571C1.57455 12.2529 1 12.8115 1 13.5029C1 14.1943 1.57455 14.7529 2.28571 14.7529H14.6085L10.3777 18.8701C9.87545 19.3584 9.87545 20.1514 10.3777 20.6396C10.8799 21.1279 11.6955 21.1279 12.1978 20.6396L18.6263 14.3896L18.6223 14.3857Z\"\n                                        fill=\"#3D3D46\" \/>\n                                <\/svg>\n                            <\/div>\n                            <p>Practice management software like Pabau supports accurate J2354 charge capture through structured treatment notes documenting dose and diagnosis.<\/p>\n                        <\/div>\n                                                <\/div>\n        <\/div>\n    \n\n\n<p class=\"wp-block-paragraph\">HCPCS Code J2354 is the billing code for the non-depot form of octreotide acetate, administered subcutaneously or intravenously at 25 mcg per unit. It is a Level II HCPCS J-code maintained by the Centers for Medicare and Medicaid Services (CMS). CMS uses it to reimburse Medicare Part B drugs administered in physician offices and outpatient settings.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Octreotide has two billing codes for two different formulations. J2354 covers the non-depot, immediate-release form used in this guide, and J2353 covers the long-acting depot form. The near-identical drug names make the two easy to confuse on a claim.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This reference covers code details, formulation differences, ICD-10 pairing, Medicare reimbursement, unit calculation, place-of-service rules, the NDC crosswalk, and common billing errors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">HCPCS Code J2354: Code details and description<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">J2354 is the standard code for physician-administered octreotide in non-depot form. Its precise descriptor matters because Medicare and commercial payers use the exact language to evaluate medical necessity and formulation appropriateness.<\/p>\n\n\n\n<table style=\"width:100%;border-collapse:separate;border-spacing:0;border-radius:12px;overflow:hidden;font-size:15px;line-height:1.5;margin:1.5em 0 2em;box-shadow:0 2px 12px rgba(0,0,0,0.08)\">\n<thead>\n<tr>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Field<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Value<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">HCPCS Code<\/td>\n<td style=\"padding:12px 16px;color:#374151\">J2354<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Long description<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Short description<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Octreotide inj, non-depot<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Code type<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Level II HCPCS J-code<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Billing unit<\/td>\n<td style=\"padding:12px 16px;color:#374151\">25 mcg per unit<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Route of administration<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Subcutaneous (SubQ) or intravenous (IV)<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Status (2026)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Active<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Maintained by<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Centers for Medicare and Medicaid Services (CMS)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n<p class=\"wp-block-paragraph\">J2354 is part of the <a href=\"https:\/\/www.cms.gov\/medicare\/coding-billing\/healthcare-common-procedure-system\" target=\"_blank\" rel=\"nofollow noopener\">HCPCS Level II codes<\/a> maintained by CMS, which cover drugs, biologicals, and other items not captured by CPT codes. The descriptor must match exactly on the CMS-1500 or 837P electronic claim. Accurate treatment notes at the point of care help prevent mismatches before submission.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.pabau.com\/cdn\/attachments\/pulse\/content-engine\/billing_codes\/hcpcs-code-j2354\/automate-claims-through-healthcode.webp\" alt=\"Pabau invoice and checkout screen for a completed appointment payment\"\/><figcaption class=\"wp-element-caption\"><em>Pabau generates an itemized invoice directly from the appointment record, so practices can confirm charges before submitting a claim for reimbursement.<\/em><\/figcaption><\/figure>\n\n\n\n<div style=\"height:35px;width:800px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\">Non-depot vs depot form: Understanding the J2354 vs J2353 distinction<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The single most common billing error with octreotide is submitting the wrong formulation code. J2353 and J2354 are not interchangeable. They describe pharmacologically distinct products with different dosing intervals, routes, and reimbursement structures.<\/p>\n\n\n\n<table style=\"width:100%;border-collapse:separate;border-spacing:0;border-radius:12px;overflow:hidden;font-size:15px;line-height:1.5;margin:1.5em 0 2em;box-shadow:0 2px 12px rgba(0,0,0,0.08)\">\n<thead>\n<tr>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Feature<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">J2354 (Non-depot)<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">J2353 (Depot \/ LAR)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Formulation<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Immediate-release solution<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Long-acting release microspheres<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Route<\/td>\n<td style=\"padding:12px 16px;color:#374151\">SubQ or IV<\/td>\n<td style=\"padding:12px 16px;color:#374151\">IM only<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Dosing interval<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Two to three times daily (typically)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Once monthly<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Billing unit<\/td>\n<td style=\"padding:12px 16px;color:#374151\">25 mcg per unit<\/td>\n<td style=\"padding:12px 16px;color:#374151\">1 mg per unit<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Brand name (Novartis)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Sandostatin<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Sandostatin LAR Depot<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">HCPCS code<\/td>\n<td style=\"padding:12px 16px;color:#374151\">J2354<\/td>\n<td style=\"padding:12px 16px;color:#374151\">J2353<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n<p class=\"wp-block-paragraph\">Non-depot octreotide (J2354) is used for acute symptom management, dose titration initiation, and patients who cannot tolerate intramuscular depot injections. The depot form (J2353) is typically used for maintenance therapy once a stable dose has been established. Submitting J2353 when the patient received the non-depot formulation constitutes a coding error that payers flag during post-payment audits.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Clinical indications and supporting ICD-10 codes for J2354<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Medical necessity is the gatekeeper for J2354 reimbursement. Every claim must be paired with a supported ICD-10 diagnosis code confirming the clinical indication. The FDA has approved octreotide acetate for three primary conditions, and Medicare Local Coverage Determinations (LCDs) from Medicare Administrative Contractors (MACs) specify which diagnoses qualify.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">FDA-approved indications<\/h3>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Acromegaly:<\/strong> reduction of growth hormone and IGF-1 levels in patients with inadequate response to surgery, radiation, or bromocriptine<\/li><li><strong>Carcinoid syndrome:<\/strong> symptomatic treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors<\/li><li><strong>VIPomas:<\/strong> treatment of profuse watery diarrhea caused by vasoactive intestinal peptide-secreting tumors<\/li><\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Supporting ICD-10 diagnosis codes<\/h3>\n\n\n\n<table style=\"width:100%;border-collapse:separate;border-spacing:0;border-radius:12px;overflow:hidden;font-size:15px;line-height:1.5;margin:1.5em 0 2em;box-shadow:0 2px 12px rgba(0,0,0,0.08)\">\n<thead>\n<tr>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">ICD-10-CM Code<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Description<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Clinical indication<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">E22.0<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Acromegaly and pituitary gigantism<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Acromegaly<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">E34.0<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Carcinoid syndrome<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Carcinoid syndrome \/ neuroendocrine tumor<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">C7A.0x0-C7A.099<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Malignant carcinoid tumors (various sites)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Carcinoid tumor (oncology)<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">E16.8<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Other specified disorders of pancreatic internal secretion<\/td>\n<td style=\"padding:12px 16px;color:#374151\">VIPoma \/ vasoactive intestinal peptide tumor<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">D3A.0x0-D3A.099<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Benign carcinoid tumors (various sites)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Benign neuroendocrine tumor<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n<p class=\"wp-block-paragraph\">Off-label use of octreotide exists for conditions such as refractory GI bleeding, portal hypertension, and certain types of chronic diarrhea. Some of these show up in functional medicine practices working alongside gastroenterology. Billing J2354 for off-label indications without specific LCD coverage creates significant audit risk. Always confirm the patient&rsquo;s diagnosis maps to an LCD-supported ICD-10 code before submitting.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Practices managing ICD-10 pairings across multiple drug therapies benefit from a structured approach to clinical documentation at the point of care. That reduces the risk of mismatched diagnosis codes at claim submission.<\/p>\n\n\n        <div id=\"pro_tip\">\n            <div class=\"img\">\n                <svg width=\"42\" height=\"42\" viewBox=\"0 0 42 42\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path fill-rule=\"evenodd\" clip-rule=\"evenodd\"\n                        d=\"M12.6383 19.5238C12.6632 21.2071 12.8734 22.9926 12.0685 24.5523C11.0341 26.8917 8.45076 28.169 7.56292 30.5918C6.63082 33.1061 7.19505 36.185 9.31371 37.9786C10.929 39.5678 13.4183 39.9873 15.6061 39.5463C17.4592 39.073 19.1049 37.8388 19.9706 36.1608C20.781 34.7141 20.7866 32.9904 20.5293 31.3985C20.1006 29.3092 18.3775 27.8705 16.9807 26.362C14.8814 24.1005 14.6684 20.6854 15.595 17.8915C16.4331 15.4768 19.0026 14.2344 20.0425 11.9461C20.7202 10.6769 20.7506 9.20327 20.6068 7.81304C20.1864 5.40098 18.3139 3.23631 15.8716 2.56674C13.9742 2.03969 11.8224 2.30052 10.1739 3.37614C8.70522 4.34688 7.5878 5.86618 7.28356 7.58178C6.76081 9.82981 7.53525 12.2822 9.20307 13.9118C10.7658 15.4741 12.4806 17.2273 12.6383 19.5238Z\"\n                        fill=\"#2BADD4\" \/>\n                    <path fill-rule=\"evenodd\" clip-rule=\"evenodd\"\n                        d=\"M22.7048 19.8387C22.6822 22.3279 24.4507 24.6234 26.7493 25.4682C28.0531 25.961 29.4725 25.9183 30.7989 25.5487C32.0575 24.9955 33.301 24.2237 34.0069 23.0092C34.8384 21.5811 35.2982 19.8286 34.7832 18.2094C34.3611 16.2507 32.8739 14.6541 31.0275 13.9426C28.6736 12.9595 25.8073 13.7942 24.1719 15.7001C23.2022 16.8366 22.6143 18.3326 22.7048 19.8387Z\"\n                        fill=\"#2BADD4\" \/>\n                <\/svg>\n            <\/div>\n            <div class=\"text\">\n                <h3>Pro Tip<\/h3>\n                <p>Before submitting J2354, verify the patient&rsquo;s ICD-10 code against your MAC&rsquo;s LCD for octreotide. LCDs vary by jurisdiction and are updated periodically. A supported diagnosis at the time of prescribing can become non-covered when a LCD is revised. Build a quarterly LCD review into your compliance calendar.<\/p>\n            <\/div>\n        <\/div>\n    \n\n\n<p class=\"wp-block-paragraph\">An <a href=\"https:\/\/pabau.com\/industry\/iv-therapy-emr-software\/\">EMR built for IV therapy<\/a> records the infusion, the units administered, and the J-code in one entry.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Medicare reimbursement for HCPCS Code J2354<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Medicare Part B reimburses physician-administered drugs under J-codes using the Average Sales Price (ASP) methodology, established under Section 1847A of the Social Security Act. For J2354, the statutory payment rate is ASP plus 6% of ASP, calculated per 25 mcg billing unit.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A 2% Medicare sequestration cut has applied to Part B drug payments since 2013, so the effective add-on works out closer to ASP plus 4.3%. Practices should verify the current effective rate before relying on it.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">ASP pricing methodology and quarterly updates<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">CMS publishes updated ASP drug pricing files quarterly, typically four times per year. The ASP reflects the weighted average sales price manufacturers report to CMS, net of rebates and discounts. Because ASP fluctuates each quarter, J2354 reimbursement rates change accordingly.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The correct approach is to reference the CMS <a href=\"https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search\/overview\" target=\"_blank\" rel=\"nofollow noopener\">Physician Fee Schedule tool<\/a> for the current quarter&rsquo;s payment limit for J2354. Stating a fixed dollar amount in billing documentation creates compliance risk when rates update. Practices should build a quarterly pricing review into their revenue cycle calendar.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Reimbursement by setting<\/h3>\n\n\n\n<table style=\"width:100%;border-collapse:separate;border-spacing:0;border-radius:12px;overflow:hidden;font-size:15px;line-height:1.5;margin:1.5em 0 2em;box-shadow:0 2px 12px rgba(0,0,0,0.08)\">\n<thead>\n<tr>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Setting<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Place of service code<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Reimbursement basis<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Notes<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Physician office<\/td>\n<td style=\"padding:12px 16px;color:#374151\">11<\/td>\n<td style=\"padding:12px 16px;color:#374151\">ASP + 6%<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Buy-and-bill model applies; practice purchases and bills payer<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Hospital outpatient<\/td>\n<td style=\"padding:12px 16px;color:#374151\">22<\/td>\n<td style=\"padding:12px 16px;color:#374151\">OPPS APC rate<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Hospital bills under Outpatient Prospective Payment System<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Off-campus outpatient<\/td>\n<td style=\"padding:12px 16px;color:#374151\">19<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Physician Fee Schedule rate<\/td>\n<td style=\"padding:12px 16px;color:#374151\">PFS rate applies when provider-based billing is not triggered<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">ASC (Ambulatory Surgical Center)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">24<\/td>\n<td style=\"padding:12px 16px;color:#374151\">ASC-specific rate<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Verify ASC payment status for J2354 with CMS ASC addendum<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n<p class=\"wp-block-paragraph\">The buy-and-bill model applies primarily in physician office settings. Under this model, the practice purchases the drug directly, administers it, and bills Medicare for reimbursement.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The practice assumes the inventory and carrying cost risk. The ASP plus 6% markup is intended to offset that cost. Practices billing under this model need robust inventory tracking and documentation to withstand a Medicare audit.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Billing guidelines and unit calculation for J2354<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Incorrect unit calculation is the second most common denial trigger for J2354 claims, after wrong formulation code. Each billing unit equals exactly 25 mcg of octreotide non-depot form. The calculation is straightforward but must be precise.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Unit calculation formula<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Units to bill = Prescribed dose in mcg divided by 25<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For example: a physician orders 100 mcg of octreotide subcutaneously. Divide 100 by 25 to get 4 units. Submit J2354 with 4 units on the claim. A common dose of 50 mcg equals 2 units, and 150 mcg equals 6 units. Always round based on actual administered dose, not prescribed dose, if a partial vial is wasted.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Billing workflow steps<\/h3>\n\n\n\n<ol class=\"wp-block-list\"><li>Confirm the administered formulation is non-depot octreotide (not Sandostatin LAR Depot)<\/li><li>Record the actual dose administered in mcg in the clinical note<\/li><li>Calculate units: divide administered dose by 25<\/li><li>Verify the patient&rsquo;s ICD-10 diagnosis code is LCD-supported for octreotide<\/li><li>Select place of service code matching the administration site<\/li><li>Include the NDC code on the claim if required by the payer (Medicaid and many commercial plans require NDC reporting)<\/li><li>Submit J2354 with the calculated unit count on the CMS-1500 or 837P claim<\/li><\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Practices that handle multiple injectable drugs benefit from a standardized documentation workflow. That keeps a consistent record of what was prescribed, next to the clinical note billers use for unit calculation.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.pabau.com\/cdn\/attachments\/pulse\/content-engine\/billing_codes\/hcpcs-code-j2354\/prescribe-controlled-drugs-safely-and-stay-compliant.webp\" alt=\"Prescribe controlled drugs safely and stay compliant\"\/><figcaption class=\"wp-element-caption\"><em>Pabau&rsquo;s prescription record keeps a running history of every medication ordered and its status. That lets practices confirm exactly what was prescribed before administering a controlled drug like octreotide.<\/em><\/figcaption><\/figure>\n\n\n\n<div style=\"height:35px;width:800px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\">NDC codes and drug crosswalk for J2354<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">NDC (National Drug Code) reporting is required for J2354 claims submitted to Medicaid. Many commercial payers also require NDC codes. The NDC must correspond to the specific octreotide product actually dispensed, not a generic placeholder. Below are common NDC mappings for octreotide non-depot products billed under J2354.<\/p>\n\n\n\n<table style=\"width:100%;border-collapse:separate;border-spacing:0;border-radius:12px;overflow:hidden;font-size:15px;line-height:1.5;margin:1.5em 0 2em;box-shadow:0 2px 12px rgba(0,0,0,0.08)\">\n<thead>\n<tr>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Product<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Manufacturer<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Strength \/ Package<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">HCPCS Code<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Sandostatin (brand)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Novartis<\/td>\n<td style=\"padding:12px 16px;color:#374151\">50 mcg\/mL, 1 mL ampule; 100 mcg\/mL, 1 mL ampule; 500 mcg\/mL, 1 mL ampule<\/td>\n<td style=\"padding:12px 16px;color:#374151\">J2354<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Octreotide acetate (generic)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Multiple manufacturers<\/td>\n<td style=\"padding:12px 16px;color:#374151\">50 mcg\/mL, 100 mcg\/mL, 200 mcg\/mL, 500 mcg\/mL (various package sizes)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">J2354<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n<p class=\"wp-block-paragraph\">Verify current NDC numbers against the <a href=\"https:\/\/clinicaltables.nlm.nih.gov\/apidoc\/hcpcs\/v3\/doc.html\" target=\"_blank\" rel=\"nofollow noopener\">NLM HCPCS API<\/a> or your pharmacy&rsquo;s current stock labeling. NDC numbers can change when manufacturers update packaging or concentrations. Always report the NDC from the specific lot administered, not a memorized number.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Medicaid programs have strict NDC reporting requirements. Billing without a valid NDC on a Medicaid claim is a common cause of avoidable denials.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Related HCPCS codes and J2354 crosswalk<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Understanding the code landscape around J2354 helps billers avoid misuse and supports accurate crosswalking when switching formulations or coding neuroendocrine tumor therapies. Billers managing a broad HCPCS code set also encounter items like B4197. These follow the same Level II coding structure as J2354.<\/p>\n\n\n\n<table style=\"width:100%;border-collapse:separate;border-spacing:0;border-radius:12px;overflow:hidden;font-size:15px;line-height:1.5;margin:1.5em 0 2em;box-shadow:0 2px 12px rgba(0,0,0,0.08)\">\n<thead>\n<tr>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Code<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Description<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Relationship to J2354<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">J2353<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Injection, octreotide, depot form for intramuscular injection, 1 mg<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Depot (LAR) formulation; billed monthly; distinct code from J2354<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">J2354<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Injection, octreotide, non-depot form, 25 mcg<\/td>\n<td style=\"padding:12px 16px;color:#374151\">This code (non-depot, immediate-release)<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">J3490<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Unclassified drugs<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Used only if octreotide is given in an unlisted form not covered by J2354\/J2353; requires invoice and documentation<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">96372<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Therapeutic, prophylactic, or diagnostic injection (subcutaneous or intramuscular)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">CPT code for subcutaneous or intramuscular administration only; billed separately when applicable in a non-facility setting<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">96374<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Therapeutic, prophylactic, or diagnostic injection, IV push, single or initial substance\/drug<\/td>\n<td style=\"padding:12px 16px;color:#374151\">CPT code for IV push administration; use instead of 96372 when J2354 is given by IV push<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n<p class=\"wp-block-paragraph\">When a patient transitions from non-depot to depot octreotide, update the HCPCS code to J2353. Recalculate units using the depot billing unit of 1 mg per unit. Both codes should never appear on the same claim for the same date of service unless two separate administrations occurred under separate clinical orders.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Prior authorization requirements<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Medicare does not universally require prior authorization for J2354, but requirements vary significantly by Medicare Advantage plan, MAC jurisdiction, and commercial payer. The <a href=\"https:\/\/www.aapc.com\/codes\/hcpcs-codes-range\/\" target=\"_blank\" rel=\"nofollow noopener\">AAPC HCPCS code reference<\/a> provides payer-specific policy notes, though practices should always verify directly with the payer before administration.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Traditional Medicare (Parts A and B):<\/strong> Prior authorization typically not required for FDA-approved indications with a supported ICD-10 code; however, MAC-specific LCDs may impose coverage criteria that function as de facto authorization requirements<\/li><li><strong>Medicare Advantage plans:<\/strong> Many plans require prior authorization; requirements vary by plan and formulary year<\/li><li><strong>Commercial payers:<\/strong> Most require prior authorization for specialty drugs including octreotide; step therapy requirements (demonstrating failure of other agents first) are common<\/li><li><strong>Medicaid:<\/strong> State-specific; prior authorization is common, particularly for non-oncology indications<\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Documentation requirements for prior authorization typically include the confirmed diagnosis with ICD-10 code and evidence of medical necessity, such as labs, imaging, or specialist notes. Payers also expect prescribing physician credentials, and for acromegaly, growth hormone and IGF-1 level data.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Storing this documentation in Pabau&rsquo;s treatment notes and patient records keeps it organized and easy to retrieve when a payer requests a prior authorization file.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Common billing errors and how to avoid them<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Octreotide claims have a higher-than-average denial rate because the code pair (J2353\/J2354), unit calculation, and LCD compliance all represent independent failure points. Addressing these proactively reduces rework and protects against post-payment audit recovery.<\/p>\n\n\n\n<table style=\"width:100%;border-collapse:separate;border-spacing:0;border-radius:12px;overflow:hidden;font-size:15px;line-height:1.5;margin:1.5em 0 2em;box-shadow:0 2px 12px rgba(0,0,0,0.08)\">\n<thead>\n<tr>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Error<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Why it happens<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">How to prevent it<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Wrong formulation code (J2353 instead of J2354)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Coder unfamiliar with non-depot vs depot distinction; EHR auto-populates wrong code<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Confirm formulation in clinical note before coding; add a coder alert to the charge master<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Incorrect unit count<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Billing prescribed dose rather than administered dose; forgetting to divide by 25<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Document administered dose in mcg in the note; use a unit calculator in the charge capture workflow<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Missing or unsupported ICD-10 code<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Diagnosis code not in the patient&rsquo;s active problem list; off-label use without LCD coverage<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Cross-reference patient diagnosis against MAC LCD before administering; do not bill for off-label indications without coverage verification<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Missing NDC on Medicaid claims<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Billing staff unaware of Medicaid NDC requirement; generic substitution with unreported NDC change<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Require NDC to be captured at drug administration; verify against dispensed product each visit<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Place of service mismatch<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Drug administered in outpatient hospital but billed under office POS 11<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Confirm actual administration site and match POS code to location; hospital billing goes through OPPS, not PFS<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n<p class=\"wp-block-paragraph\">Practices with an active HIPAA compliance program tend to catch these errors at the charge capture stage rather than at claims adjudication. Structured medical office compliance workflows make that possible, and significantly reduce the cost of rework. Regular internal audits of octreotide claims, spot-checking unit counts and ICD-10 pairings, are an effective safeguard against systematic billing errors.<\/p>\n\n\n        <div id=\"pro_tip\">\n            <div class=\"img\">\n                <svg width=\"42\" height=\"42\" viewBox=\"0 0 42 42\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path fill-rule=\"evenodd\" clip-rule=\"evenodd\"\n                        d=\"M12.6383 19.5238C12.6632 21.2071 12.8734 22.9926 12.0685 24.5523C11.0341 26.8917 8.45076 28.169 7.56292 30.5918C6.63082 33.1061 7.19505 36.185 9.31371 37.9786C10.929 39.5678 13.4183 39.9873 15.6061 39.5463C17.4592 39.073 19.1049 37.8388 19.9706 36.1608C20.781 34.7141 20.7866 32.9904 20.5293 31.3985C20.1006 29.3092 18.3775 27.8705 16.9807 26.362C14.8814 24.1005 14.6684 20.6854 15.595 17.8915C16.4331 15.4768 19.0026 14.2344 20.0425 11.9461C20.7202 10.6769 20.7506 9.20327 20.6068 7.81304C20.1864 5.40098 18.3139 3.23631 15.8716 2.56674C13.9742 2.03969 11.8224 2.30052 10.1739 3.37614C8.70522 4.34688 7.5878 5.86618 7.28356 7.58178C6.76081 9.82981 7.53525 12.2822 9.20307 13.9118C10.7658 15.4741 12.4806 17.2273 12.6383 19.5238Z\"\n                        fill=\"#2BADD4\" \/>\n                    <path fill-rule=\"evenodd\" clip-rule=\"evenodd\"\n                        d=\"M22.7048 19.8387C22.6822 22.3279 24.4507 24.6234 26.7493 25.4682C28.0531 25.961 29.4725 25.9183 30.7989 25.5487C32.0575 24.9955 33.301 24.2237 34.0069 23.0092C34.8384 21.5811 35.2982 19.8286 34.7832 18.2094C34.3611 16.2507 32.8739 14.6541 31.0275 13.9426C28.6736 12.9595 25.8073 13.7942 24.1719 15.7001C23.2022 16.8366 22.6143 18.3326 22.7048 19.8387Z\"\n                        fill=\"#2BADD4\" \/>\n                <\/svg>\n            <\/div>\n            <div class=\"text\">\n                <h3>Pro Tip<\/h3>\n                <p>Run a monthly query in your practice management system for all J2354 claims submitted in the prior period. Filter for denied claims and categorize by denial reason. If more than 10% of denials share one category (wrong code, wrong units, unsupported ICD-10), that is a process failure, not a one-off error. Fix the workflow, not just the individual claim.<\/p>\n            <\/div>\n        <\/div>\n    \n\n\n<h2 class=\"wp-block-heading\">Related HCPCS codes<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/pabau.com\/procedure-codes\/hcpcs-code-j1885\/\">HCPCS code J1885 \u2014 Ketorolac<\/a><\/li>\n\n\n<li><a href=\"https:\/\/pabau.com\/procedure-codes\/hcpcs-code-j2371\/\">HCPCS code J2371 \u2014 Phenylephrine hydrochloride 20 mcg<\/a><\/li>\n\n\n<li><a href=\"https:\/\/pabau.com\/procedure-codes\/hcpcs-code-j2405\/\">HCPCS code J2405 \u2014 Injection, Ondansetron Hydrochloride, per 1 mg<\/a><\/li>\n\n\n<li><a href=\"https:\/\/pabau.com\/procedure-codes\/hcpcs-code-j0129\/\">HCPCS Code J0129 \u2014 Abatacept (Orencia)<\/a><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">How Pabau supports accurate documentation for J2354 claims<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Most J2354 denials start before the claim is even coded. A dose scribbled on paper, a diagnosis missing from the note, or an inconsistent formulation name across visits all create the same downstream problem. Getting the underlying documentation right is what makes accurate billing possible.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Endocrinology practices, oncology clinics. Pabau gives them a structured treatment note for every administration. It captures the formulation, dose, and diagnosis code in one place, rather than scattered across paper charts or a separate spreadsheet.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">That consistency is what a biller needs to translate a visit into an accurate claim, whichever formulation code applies. Practices spend less time chasing missing details after the fact and more time on patient care.<\/p>\n\n\n        <div id=\"book_a_demo\">\n            <div class=\"left-side\">\n                <div class=\"logo\">\n                    <img decoding=\"async\"\n                        src=\"https:\/\/pabau.com\/wp-content\/uploads\/2026\/01\/Logo.svg\"\n                        alt=\"Logo\"\n                        loading=\"lazy\"\n                    \/>\n                <\/div>\n\n                <h3 class=\"heading\">\n                    Keep J2354 documentation accurate and consistent                <\/h3>\n\n                <p class=\"description\">\n                    Pabau&rsquo;s treatment notes capture the formulation, dose, and diagnosis for every octreotide administration in one patient record. Your billing team gets everything it needs to code the claim correctly.                <\/p>\n\n                <div class=\"button-group\">\n                    <a href=\"\/book-demo\/\" class=\"btn btn-scale-effect btn-cta-color btn-md\">\n                        <span class=\"btn-text\">Book a demo<\/span>\n                        <div class=\"btn-icon btn-icon-right\" aria-hidden=\"true\">\n                            <svg\n                                width=\"14\"\n                                height=\"12\"\n                                viewBox=\"0 0 14 12\"\n                                fill=\"none\"\n                                xmlns=\"http:\/\/www.w3.org\/2000\/svg\"\n                            >\n                                <path\n                                    d=\"M0.75 4.77295C0.335786 4.77295 0 5.10874 0 5.52295C0 5.93716 0.335786 6.27295 0.75 6.27295V5.52295V4.77295ZM13.2803 6.05328C13.5732 5.76039 13.5732 5.28551 13.2803 4.99262L8.50736 0.219648C8.21447 -0.073245 7.73959 -0.073245 7.4467 0.219648C7.15381 0.512542 7.15381 0.987415 7.4467 1.28031L11.6893 5.52295L7.4467 9.76559C7.15381 10.0585 7.15381 10.5334 7.4467 10.8263C7.73959 11.1191 8.21447 11.1191 8.50736 10.8263L13.2803 6.05328ZM0.75 5.52295V6.27295L12.75 6.27295V5.52295V4.77295L0.75 4.77295V5.52295Z\"\n                                    fill=\"currentColor\"\n                                ><\/path>\n                            <\/svg>\n                        <\/div>\n                    <\/a>\n                <\/div>\n            <\/div>\n\n            <div class=\"right-side\">\n                <img decoding=\"async\"\n                    src=\"https:\/\/pabau.com\/wp-content\/uploads\/2026\/01\/Home-Page-Concept-4.webp\"\n                    alt=\"Pabau treatment notes and patient record dashboard\"\n                    loading=\"lazy\"\n                \/>\n            <\/div>\n        <\/div>\n        \n\n\n<h2 class=\"wp-block-heading\">Conclusion<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Get the formulation code right, calculate units from the administered dose, and pair the claim with an LCD-supported diagnosis, and most J2354 denials never happen. Skip any one of the three and the claim comes back, regardless of how quickly the rest of the paperwork moves.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The fix is rarely more coding staff. It&rsquo;s a documentation habit that captures dose, formulation, and diagnosis at the point of care, before a biller has to reconstruct it after the fact.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pabau.com\/book-demo\/\">Book a demo<\/a> to see how Pabau&rsquo;s treatment notes keep that detail consistent for every octreotide administration.<\/p>\n\n\n        <div id=\"expert_picks\">\n            <div class=\"header\">\n                                    <img decoding=\"async\" src=\"https:\/\/pabau.com\/wp-content\/uploads\/2025\/11\/Expert-Picks.svg\" alt=\"Continue your research\" height=\"42\" width=\"42\">\n                                <h3>Continue your research<\/h3>\n            <\/div>\n            <div class=\"content\">\n                                                            <div class=\"item\">\n                            <div>\n                                <svg width=\"20\" height=\"27\" viewBox=\"0 0 20 27\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                                    <path\n                                        d=\"M18.6223 14.3857C19.1246 13.8975 19.1246 13.1045 18.6223 12.6162L12.1938 6.36621C11.6915 5.87793 10.8759 5.87793 10.3737 6.36621C9.87143 6.85449 9.87143 7.64746 10.3737 8.13574L14.6125 12.2529H2.28571C1.57455 12.2529 1 12.8115 1 13.5029C1 14.1943 1.57455 14.7529 2.28571 14.7529H14.6085L10.3777 18.8701C9.87545 19.3584 9.87545 20.1514 10.3777 20.6396C10.8799 21.1279 11.6955 21.1279 12.1978 20.6396L18.6263 14.3896L18.6223 14.3857Z\"\n                                        fill=\"#54B2D3\" \/>\n                                <\/svg>\n                            <\/div>\n                            <p><strong>Billing another physician-administered oncology drug?<\/strong> <a href=\"https:\/\/pabau.com\/procedure-codes\/hcpcs-code-j9312\/\">J9312<\/a> covers rituximab, sharing the same ASP-based Medicare reimbursement approach as J2354.<\/p>\n                        <\/div>\n                                                                                <div class=\"item\">\n                            <div>\n                                <svg width=\"20\" height=\"27\" viewBox=\"0 0 20 27\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                                    <path\n                                        d=\"M18.6223 14.3857C19.1246 13.8975 19.1246 13.1045 18.6223 12.6162L12.1938 6.36621C11.6915 5.87793 10.8759 5.87793 10.3737 6.36621C9.87143 6.85449 9.87143 7.64746 10.3737 8.13574L14.6125 12.2529H2.28571C1.57455 12.2529 1 12.8115 1 13.5029C1 14.1943 1.57455 14.7529 2.28571 14.7529H14.6085L10.3777 18.8701C9.87545 19.3584 9.87545 20.1514 10.3777 20.6396C10.8799 21.1279 11.6955 21.1279 12.1978 20.6396L18.6263 14.3896L18.6223 14.3857Z\"\n                                        fill=\"#54B2D3\" \/>\n                                <\/svg>\n                            <\/div>\n                            <p><strong>Coding a home injectable therapy that doesn&rsquo;t fit a named code?<\/strong> <a href=\"https:\/\/pabau.com\/procedure-codes\/hcpcs-code-s9542\/\">S9542<\/a> is the not-otherwise-classified per diem code for home injectable drug administration.<\/p>\n                        <\/div>\n                                                                                <div class=\"item\">\n                            <div>\n                                <svg width=\"20\" height=\"27\" viewBox=\"0 0 20 27\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                                    <path\n                                        d=\"M18.6223 14.3857C19.1246 13.8975 19.1246 13.1045 18.6223 12.6162L12.1938 6.36621C11.6915 5.87793 10.8759 5.87793 10.3737 6.36621C9.87143 6.85449 9.87143 7.64746 10.3737 8.13574L14.6125 12.2529H2.28571C1.57455 12.2529 1 12.8115 1 13.5029C1 14.1943 1.57455 14.7529 2.28571 14.7529H14.6085L10.3777 18.8701C9.87545 19.3584 9.87545 20.1514 10.3777 20.6396C10.8799 21.1279 11.6955 21.1279 12.1978 20.6396L18.6263 14.3896L18.6223 14.3857Z\"\n                                        fill=\"#54B2D3\" \/>\n                                <\/svg>\n                            <\/div>\n                            <p><strong>Need a quick endocrinology knowledge check for your team?<\/strong> The <a href=\"https:\/\/pabau.com\/templates\/endocrinology-quiz\/\">endocrinology quiz<\/a> template covers hormones, feedback mechanisms, and thyroid and adrenal disorders.<\/p>\n                        <\/div>\n                                                <\/div>\n        <\/div>\n    \n\n\n<h2 class=\"wp-block-heading\">Frequently asked questions<\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1785234741447\"><h3 class=\"schema-faq-question\">What is HCPCS Code J2354 used for?<\/h3> <p class=\"schema-faq-answer\">HCPCS Code J2354 is the billing code for injection of octreotide acetate in non-depot, immediate-release form. It&rsquo;s administered subcutaneously or intravenously at 25 mcg per billing unit. Practices use it to bill Medicare Part B and commercial payers for physician-administered octreotide in office and outpatient settings. Covered conditions include acromegaly, carcinoid syndrome, and VIPomas.<\/p><\/div> <div class=\"schema-faq-section\" id=\"faq-question-1785234741448\"><h3 class=\"schema-faq-question\">What is the difference between J2353 and J2354?<\/h3> <p class=\"schema-faq-answer\">J2354 covers octreotide in non-depot form: immediate-release, given subcutaneously or IV, billed at 25 mcg per unit. J2353 covers the depot form instead: long-acting release, given intramuscularly once monthly and billed at 1 mg per unit. The two codes are never interchangeable. Submitting the wrong formulation code is the leading cause of octreotide claim denials.<\/p><\/div> <div class=\"schema-faq-section\" id=\"faq-question-1785234741449\"><h3 class=\"schema-faq-question\">How many units of J2354 can be billed per visit?<\/h3> <p class=\"schema-faq-answer\">There is no fixed per-visit unit cap specified in the HCPCS descriptor, but medical necessity and payer policy govern the maximum billable dose. Calculate units by dividing the administered dose in mcg by 25 (e.g., 100 mcg = 4 units). Always document the administered dose in the clinical note and verify the unit count against the prescribing order before submitting.<\/p><\/div> <div class=\"schema-faq-section\" id=\"faq-question-1785234741450\"><h3 class=\"schema-faq-question\">How is J2354 reimbursed by Medicare?<\/h3> <p class=\"schema-faq-answer\">Medicare Part B reimburses J2354 at the statutory rate of ASP plus 6% of ASP per billing unit, calculated per 25 mcg. A 2% sequestration cut has applied to Part B drug payments since 2013, so the effective add-on is closer to ASP plus 4.3%. The ASP updates quarterly. Verify the current payment amount using the CMS ASP Pricing Files or the Physician Fee Schedule lookup tool rather than relying on previously recorded figures.<\/p><\/div> <div class=\"schema-faq-section\" id=\"faq-question-1785234741451\"><h3 class=\"schema-faq-question\">Does J2354 require prior authorization?<\/h3> <p class=\"schema-faq-answer\">Traditional Medicare does not universally require prior authorization for J2354 when it&rsquo;s used for an FDA-approved indication with a supported ICD-10 code. Medicare Advantage plans, commercial payers, and Medicaid programs frequently do require it. Requirements vary by plan and jurisdiction, so verify directly with the payer before administering octreotide for each patient.<\/p><\/div> <div class=\"schema-faq-section\" id=\"faq-question-1785234741452\"><h3 class=\"schema-faq-question\">What ICD-10 codes support medical necessity for J2354?<\/h3> <p class=\"schema-faq-answer\">Four ICD-10 codes commonly support medical necessity for J2354. E22.0 covers acromegaly and pituitary gigantism, and E34.0 covers carcinoid syndrome. The C7A series covers malignant carcinoid tumors, and E16.8 covers other pancreatic disorders, including VIPomas. Confirm the specific supported codes against your MAC&rsquo;s LCD for octreotide, since coverage criteria vary by jurisdiction.<\/p><\/div> <div class=\"schema-faq-section\" id=\"faq-question-1785234741453\"><h3 class=\"schema-faq-question\">Can J2354 be billed in an ASC setting?<\/h3> <p class=\"schema-faq-answer\">J2354 can be administered in an Ambulatory Surgical Center (ASC), but reimbursement follows ASC-specific rates rather than the physician office ASP + 6% rate. Verify J2354&rsquo;s ASC payment status using the CMS ASC payment addendum for the current year before assuming the standard reimbursement rate applies in that setting.<\/p><\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>HCPCS Code J2354 is the billing code for the non-depot form of octreotide acetate, administered subcutaneously or intravenously at 25 mcg per unit. It is a Level II HCPCS J-code maintained by the Centers for Medicare and Medicaid Services (CMS). CMS uses it to reimburse Medicare Part B drugs administered in physician offices and outpatient [&hellip;]<\/p>\n","protected":false},"author":81,"featured_media":168452,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_linkdex":"","_yoast_wpseo_content_score":"","_yoast_wpseo_is_cornerstone":"","_yoast_wpseo_keywordsynonyms":"","_yoast_wpseo_focuskw_text_input":"","_seo_original_html":"","footnotes":""},"categories":[1433,1548,1117],"tags":[2957,2958,2953,2959,1687],"class_list":["post-168454","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-billing-codes","category-hcpcs","category-metabolic-health","tag-drug-administration-billing","tag-hcpcs-billing-guide","tag-j-code-billing","tag-medicare-part-b-drugs","tag-oncology-billing"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.3 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HCPCS Code J2354: Octreotide non-depot injection billing guide<\/title>\n<meta name=\"description\" content=\"HCPCS Code J2354 covers non-depot octreotide, billed at 25 mcg per unit via subcutaneous or IV injection under Medicare Part B.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HCPCS Code J2354: Octreotide non-depot injection billing guide\" \/>\n<meta property=\"og:description\" content=\"HCPCS Code J2354 covers non-depot octreotide, billed at 25 mcg per unit via subcutaneous or IV injection under Medicare Part B.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/\" \/>\n<meta property=\"og:site_name\" content=\"Pabau\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Pabau\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-28T14:04:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-17T12:08:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pabau.com\/wp-content\/uploads\/2026\/07\/hcpcs-code-j2354.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Aleksandar Kochovski\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@pabaucrm\" \/>\n<meta name=\"twitter:site\" content=\"@pabaucrm\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Aleksandar Kochovski\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/\"},\"author\":{\"name\":\"Aleksandar Kochovski\",\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/#\\\/schema\\\/person\\\/73b672a49e20bfba8161e3c17ee3dda2\"},\"headline\":\"HCPCS Code J2354: Octreotide non-depot injection billing guide\",\"datePublished\":\"2026-07-28T14:04:27+00:00\",\"dateModified\":\"2026-08-17T12:08:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/\"},\"wordCount\":2750,\"publisher\":{\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pabau.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/hcpcs-code-j2354.webp\",\"keywords\":[\"Drug Administration Billing\",\"Hcpcs Billing Guide\",\"J Code Billing\",\"Medicare Part B Drugs\",\"Oncology Billing\"],\"articleSection\":[\"Billing Codes\",\"HCPCS\",\"Metabolic Health\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"FAQPage\"],\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/\",\"url\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/\",\"name\":\"HCPCS Code J2354: Octreotide non-depot injection billing guide\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pabau.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/hcpcs-code-j2354.webp\",\"datePublished\":\"2026-07-28T14:04:27+00:00\",\"dateModified\":\"2026-08-17T12:08:21+00:00\",\"description\":\"HCPCS Code J2354 covers non-depot octreotide, billed at 25 mcg per unit via subcutaneous or IV injection under Medicare Part B.\",\"mainEntity\":[{\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741447\"},{\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741448\"},{\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741449\"},{\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741450\"},{\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741451\"},{\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741452\"},{\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741453\"}],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#primaryimage\",\"url\":\"https:\\\/\\\/pabau.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/hcpcs-code-j2354.webp\",\"contentUrl\":\"https:\\\/\\\/pabau.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/hcpcs-code-j2354.webp\",\"width\":1200,\"height\":630},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/pabau.com\\\/fr\\\/\",\"name\":\"Pabau\",\"description\":\"Clinic Software for your Business | Go Paperless Today\",\"publisher\":{\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pabau.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/#organization\",\"name\":\"Pabau\",\"url\":\"https:\\\/\\\/pabau.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/pabau.com\\\/wp-content\\\/uploads\\\/2022\\\/05\\\/Logo-4-e1654525062364.png\",\"contentUrl\":\"https:\\\/\\\/pabau.com\\\/wp-content\\\/uploads\\\/2022\\\/05\\\/Logo-4-e1654525062364.png\",\"width\":736,\"height\":195,\"caption\":\"Pabau\"},\"image\":{\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/Pabau\\\/\",\"https:\\\/\\\/x.com\\\/pabaucrm\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/pabau-ltd\\\/\",\"https:\\\/\\\/www.instagram.com\\\/pabausoftware\\\/\"],\"description\":\"Pabau is an all-in-one healthcare practice management software platform designed for clinics, medspas, therapists, and medical professionals. It combines scheduling, electronic health records, clinical forms, payments, marketing automation, reporting, and patient engagement tools into one secure cloud system to help practices streamline operations and grow their business.\",\"foundingDate\":\"2011-10-20\",\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":\"201\",\"maxValue\":\"500\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/#\\\/schema\\\/person\\\/73b672a49e20bfba8161e3c17ee3dda2\",\"name\":\"Aleksandar Kochovski\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/pabau.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-aleksandar-kochovski-profile-picture-96x96.jpeg\",\"url\":\"https:\\\/\\\/pabau.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-aleksandar-kochovski-profile-picture-96x96.jpeg\",\"contentUrl\":\"https:\\\/\\\/pabau.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-aleksandar-kochovski-profile-picture-96x96.jpeg\",\"caption\":\"Aleksandar Kochovski\"},\"description\":\"Aleksandar is a content strategist and editor working in tech publishing, with a background in higher education. He specializes in topics around compliance in software solutions. When he's not writing at Pabau, you can find him tending to his bonsai collection or hitting the gym.\",\"url\":\"https:\\\/\\\/pabau.com\\\/fr\\\/blog\\\/author\\\/aleksandar-kochovski\\\/\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741447\",\"position\":1,\"url\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741447\",\"name\":\"What is HCPCS Code J2354 used for?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"HCPCS Code J2354 is the billing code for injection of octreotide acetate in non-depot, immediate-release form. It's administered subcutaneously or intravenously at 25 mcg per billing unit. Practices use it to bill Medicare Part B and commercial payers for physician-administered octreotide in office and outpatient settings. Covered conditions include acromegaly, carcinoid syndrome, and VIPomas.\",\"inLanguage\":\"fr-FR\"},\"inLanguage\":\"fr-FR\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741448\",\"position\":2,\"url\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741448\",\"name\":\"What is the difference between J2353 and J2354?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"J2354 covers octreotide in non-depot form: immediate-release, given subcutaneously or IV, billed at 25 mcg per unit. J2353 covers the depot form instead: long-acting release, given intramuscularly once monthly and billed at 1 mg per unit. The two codes are never interchangeable. Submitting the wrong formulation code is the leading cause of octreotide claim denials.\",\"inLanguage\":\"fr-FR\"},\"inLanguage\":\"fr-FR\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741449\",\"position\":3,\"url\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741449\",\"name\":\"How many units of J2354 can be billed per visit?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"There is no fixed per-visit unit cap specified in the HCPCS descriptor, but medical necessity and payer policy govern the maximum billable dose. Calculate units by dividing the administered dose in mcg by 25 (e.g., 100 mcg = 4 units). Always document the administered dose in the clinical note and verify the unit count against the prescribing order before submitting.\",\"inLanguage\":\"fr-FR\"},\"inLanguage\":\"fr-FR\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741450\",\"position\":4,\"url\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741450\",\"name\":\"How is J2354 reimbursed by Medicare?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Medicare Part B reimburses J2354 at the statutory rate of ASP plus 6% of ASP per billing unit, calculated per 25 mcg. A 2% sequestration cut has applied to Part B drug payments since 2013, so the effective add-on is closer to ASP plus 4.3%. The ASP updates quarterly. Verify the current payment amount using the CMS ASP Pricing Files or the Physician Fee Schedule lookup tool rather than relying on previously recorded figures.\",\"inLanguage\":\"fr-FR\"},\"inLanguage\":\"fr-FR\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741451\",\"position\":5,\"url\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741451\",\"name\":\"Does J2354 require prior authorization?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Traditional Medicare does not universally require prior authorization for J2354 when it's used for an FDA-approved indication with a supported ICD-10 code. Medicare Advantage plans, commercial payers, and Medicaid programs frequently do require it. Requirements vary by plan and jurisdiction, so verify directly with the payer before administering octreotide for each patient.\",\"inLanguage\":\"fr-FR\"},\"inLanguage\":\"fr-FR\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741452\",\"position\":6,\"url\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741452\",\"name\":\"What ICD-10 codes support medical necessity for J2354?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Four ICD-10 codes commonly support medical necessity for J2354. E22.0 covers acromegaly and pituitary gigantism, and E34.0 covers carcinoid syndrome. The C7A series covers malignant carcinoid tumors, and E16.8 covers other pancreatic disorders, including VIPomas. Confirm the specific supported codes against your MAC's LCD for octreotide, since coverage criteria vary by jurisdiction.\",\"inLanguage\":\"fr-FR\"},\"inLanguage\":\"fr-FR\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741453\",\"position\":7,\"url\":\"https:\\\/\\\/pabau.com\\\/fr\\\/procedure-codes\\\/hcpcs-code-j2354\\\/#faq-question-1785234741453\",\"name\":\"Can J2354 be billed in an ASC setting?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"J2354 can be administered in an Ambulatory Surgical Center (ASC), but reimbursement follows ASC-specific rates rather than the physician office ASP + 6% rate. Verify J2354's ASC payment status using the CMS ASC payment addendum for the current year before assuming the standard reimbursement rate applies in that setting.\",\"inLanguage\":\"fr-FR\"},\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HCPCS Code J2354: Octreotide non-depot injection billing guide","description":"HCPCS Code J2354 covers non-depot octreotide, billed at 25 mcg per unit via subcutaneous or IV injection under Medicare Part B.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/","og_locale":"fr_FR","og_type":"article","og_title":"HCPCS Code J2354: Octreotide non-depot injection billing guide","og_description":"HCPCS Code J2354 covers non-depot octreotide, billed at 25 mcg per unit via subcutaneous or IV injection under Medicare Part B.","og_url":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/","og_site_name":"Pabau","article_publisher":"https:\/\/www.facebook.com\/Pabau\/","article_published_time":"2026-07-28T14:04:27+00:00","article_modified_time":"2026-08-17T12:08:21+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/pabau.com\/wp-content\/uploads\/2026\/07\/hcpcs-code-j2354.webp","type":"image\/webp"}],"author":"Aleksandar Kochovski","twitter_card":"summary_large_image","twitter_creator":"@pabaucrm","twitter_site":"@pabaucrm","twitter_misc":{"\u00c9crit par":"Aleksandar Kochovski","Dur\u00e9e de lecture estim\u00e9e":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#article","isPartOf":{"@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/"},"author":{"name":"Aleksandar Kochovski","@id":"https:\/\/pabau.com\/fr\/#\/schema\/person\/73b672a49e20bfba8161e3c17ee3dda2"},"headline":"HCPCS Code J2354: Octreotide non-depot injection billing guide","datePublished":"2026-07-28T14:04:27+00:00","dateModified":"2026-08-17T12:08:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/"},"wordCount":2750,"publisher":{"@id":"https:\/\/pabau.com\/fr\/#organization"},"image":{"@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#primaryimage"},"thumbnailUrl":"https:\/\/pabau.com\/wp-content\/uploads\/2026\/07\/hcpcs-code-j2354.webp","keywords":["Drug Administration Billing","Hcpcs Billing Guide","J Code Billing","Medicare Part B Drugs","Oncology Billing"],"articleSection":["Billing Codes","HCPCS","Metabolic Health"],"inLanguage":"fr-FR"},{"@type":["WebPage","FAQPage"],"@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/","url":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/","name":"HCPCS Code J2354: Octreotide non-depot injection billing guide","isPartOf":{"@id":"https:\/\/pabau.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#primaryimage"},"image":{"@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#primaryimage"},"thumbnailUrl":"https:\/\/pabau.com\/wp-content\/uploads\/2026\/07\/hcpcs-code-j2354.webp","datePublished":"2026-07-28T14:04:27+00:00","dateModified":"2026-08-17T12:08:21+00:00","description":"HCPCS Code J2354 covers non-depot octreotide, billed at 25 mcg per unit via subcutaneous or IV injection under Medicare Part B.","mainEntity":[{"@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741447"},{"@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741448"},{"@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741449"},{"@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741450"},{"@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741451"},{"@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741452"},{"@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741453"}],"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#primaryimage","url":"https:\/\/pabau.com\/wp-content\/uploads\/2026\/07\/hcpcs-code-j2354.webp","contentUrl":"https:\/\/pabau.com\/wp-content\/uploads\/2026\/07\/hcpcs-code-j2354.webp","width":1200,"height":630},{"@type":"WebSite","@id":"https:\/\/pabau.com\/fr\/#website","url":"https:\/\/pabau.com\/fr\/","name":"Pabau","description":"Clinic Software for your Business | Go Paperless Today","publisher":{"@id":"https:\/\/pabau.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pabau.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/pabau.com\/fr\/#organization","name":"Pabau","url":"https:\/\/pabau.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/pabau.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/pabau.com\/wp-content\/uploads\/2022\/05\/Logo-4-e1654525062364.png","contentUrl":"https:\/\/pabau.com\/wp-content\/uploads\/2022\/05\/Logo-4-e1654525062364.png","width":736,"height":195,"caption":"Pabau"},"image":{"@id":"https:\/\/pabau.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Pabau\/","https:\/\/x.com\/pabaucrm","https:\/\/www.linkedin.com\/company\/pabau-ltd\/","https:\/\/www.instagram.com\/pabausoftware\/"],"description":"Pabau is an all-in-one healthcare practice management software platform designed for clinics, medspas, therapists, and medical professionals. It combines scheduling, electronic health records, clinical forms, payments, marketing automation, reporting, and patient engagement tools into one secure cloud system to help practices streamline operations and grow their business.","foundingDate":"2011-10-20","numberOfEmployees":{"@type":"QuantitativeValue","minValue":"201","maxValue":"500"}},{"@type":"Person","@id":"https:\/\/pabau.com\/fr\/#\/schema\/person\/73b672a49e20bfba8161e3c17ee3dda2","name":"Aleksandar Kochovski","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/pabau.com\/wp-content\/uploads\/2026\/06\/cropped-aleksandar-kochovski-profile-picture-96x96.jpeg","url":"https:\/\/pabau.com\/wp-content\/uploads\/2026\/06\/cropped-aleksandar-kochovski-profile-picture-96x96.jpeg","contentUrl":"https:\/\/pabau.com\/wp-content\/uploads\/2026\/06\/cropped-aleksandar-kochovski-profile-picture-96x96.jpeg","caption":"Aleksandar Kochovski"},"description":"Aleksandar is a content strategist and editor working in tech publishing, with a background in higher education. He specializes in topics around compliance in software solutions. When he's not writing at Pabau, you can find him tending to his bonsai collection or hitting the gym.","url":"https:\/\/pabau.com\/fr\/blog\/author\/aleksandar-kochovski\/"},{"@type":"Question","@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741447","position":1,"url":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741447","name":"What is HCPCS Code J2354 used for?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"HCPCS Code J2354 is the billing code for injection of octreotide acetate in non-depot, immediate-release form. It's administered subcutaneously or intravenously at 25 mcg per billing unit. Practices use it to bill Medicare Part B and commercial payers for physician-administered octreotide in office and outpatient settings. Covered conditions include acromegaly, carcinoid syndrome, and VIPomas.","inLanguage":"fr-FR"},"inLanguage":"fr-FR"},{"@type":"Question","@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741448","position":2,"url":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741448","name":"What is the difference between J2353 and J2354?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"J2354 covers octreotide in non-depot form: immediate-release, given subcutaneously or IV, billed at 25 mcg per unit. J2353 covers the depot form instead: long-acting release, given intramuscularly once monthly and billed at 1 mg per unit. The two codes are never interchangeable. Submitting the wrong formulation code is the leading cause of octreotide claim denials.","inLanguage":"fr-FR"},"inLanguage":"fr-FR"},{"@type":"Question","@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741449","position":3,"url":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741449","name":"How many units of J2354 can be billed per visit?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"There is no fixed per-visit unit cap specified in the HCPCS descriptor, but medical necessity and payer policy govern the maximum billable dose. Calculate units by dividing the administered dose in mcg by 25 (e.g., 100 mcg = 4 units). Always document the administered dose in the clinical note and verify the unit count against the prescribing order before submitting.","inLanguage":"fr-FR"},"inLanguage":"fr-FR"},{"@type":"Question","@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741450","position":4,"url":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741450","name":"How is J2354 reimbursed by Medicare?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Medicare Part B reimburses J2354 at the statutory rate of ASP plus 6% of ASP per billing unit, calculated per 25 mcg. A 2% sequestration cut has applied to Part B drug payments since 2013, so the effective add-on is closer to ASP plus 4.3%. The ASP updates quarterly. Verify the current payment amount using the CMS ASP Pricing Files or the Physician Fee Schedule lookup tool rather than relying on previously recorded figures.","inLanguage":"fr-FR"},"inLanguage":"fr-FR"},{"@type":"Question","@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741451","position":5,"url":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741451","name":"Does J2354 require prior authorization?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Traditional Medicare does not universally require prior authorization for J2354 when it's used for an FDA-approved indication with a supported ICD-10 code. Medicare Advantage plans, commercial payers, and Medicaid programs frequently do require it. Requirements vary by plan and jurisdiction, so verify directly with the payer before administering octreotide for each patient.","inLanguage":"fr-FR"},"inLanguage":"fr-FR"},{"@type":"Question","@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741452","position":6,"url":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741452","name":"What ICD-10 codes support medical necessity for J2354?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Four ICD-10 codes commonly support medical necessity for J2354. E22.0 covers acromegaly and pituitary gigantism, and E34.0 covers carcinoid syndrome. The C7A series covers malignant carcinoid tumors, and E16.8 covers other pancreatic disorders, including VIPomas. Confirm the specific supported codes against your MAC's LCD for octreotide, since coverage criteria vary by jurisdiction.","inLanguage":"fr-FR"},"inLanguage":"fr-FR"},{"@type":"Question","@id":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741453","position":7,"url":"https:\/\/pabau.com\/fr\/procedure-codes\/hcpcs-code-j2354\/#faq-question-1785234741453","name":"Can J2354 be billed in an ASC setting?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"J2354 can be administered in an Ambulatory Surgical Center (ASC), but reimbursement follows ASC-specific rates rather than the physician office ASP + 6% rate. Verify J2354's ASC payment status using the CMS ASC payment addendum for the current year before assuming the standard reimbursement rate applies in that setting.","inLanguage":"fr-FR"},"inLanguage":"fr-FR"}]}},"yoast":{"focus_keyword":"HCPCS Code J2354","seo_title":"HCPCS Code J2354: Octreotide non-depot injection billing guide","meta_description":"HCPCS Code J2354 covers non-depot octreotide, billed at 25 mcg per unit via subcutaneous or IV injection under Medicare Part B.","content_score":"","is_cornerstone":"","related_keyphrases":[{"keyword":"J2354 medicare reimbursement","synonyms":["J2354 octreotide","J2354 non-depot octreotide","octreotide acetate HCPCS","HCPCS J2354"]},{"keyword":"J2354 ICD-10 codes","synonyms":["J2354 octreotide","J2354 non-depot octreotide","octreotide acetate HCPCS","HCPCS J2354"]},{"keyword":"J2354 fee schedule","synonyms":["J2354 octreotide","J2354 non-depot octreotide","octreotide acetate HCPCS","HCPCS J2354"]},{"keyword":"octreotide billing","synonyms":["J2354 octreotide","J2354 non-depot octreotide","octreotide acetate HCPCS","HCPCS J2354"]},{"keyword":"buy and bill drug administration","synonyms":["J2354 octreotide","J2354 non-depot octreotide","octreotide acetate HCPCS","HCPCS J2354"]}]},"_links":{"self":[{"href":"https:\/\/pabau.com\/fr\/wp-json\/wp\/v2\/posts\/168454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pabau.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pabau.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pabau.com\/fr\/wp-json\/wp\/v2\/users\/81"}],"replies":[{"embeddable":true,"href":"https:\/\/pabau.com\/fr\/wp-json\/wp\/v2\/comments?post=168454"}],"version-history":[{"count":3,"href":"https:\/\/pabau.com\/fr\/wp-json\/wp\/v2\/posts\/168454\/revisions"}],"predecessor-version":[{"id":182786,"href":"https:\/\/pabau.com\/fr\/wp-json\/wp\/v2\/posts\/168454\/revisions\/182786"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pabau.com\/fr\/wp-json\/wp\/v2\/media\/168452"}],"wp:attachment":[{"href":"https:\/\/pabau.com\/fr\/wp-json\/wp\/v2\/media?parent=168454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pabau.com\/fr\/wp-json\/wp\/v2\/categories?post=168454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pabau.com\/fr\/wp-json\/wp\/v2\/tags?post=168454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}